HIV infection


More than 75 million people worldwide have been infected with human immunodeficiency virus (HIV), and there are now approximately 37 million individuals living with the infection. Untreated HIV replication causes progressive CD4+ T cell loss and a wide range of immunological abnormalities, leading to an increased risk of infectious and oncological complications. HIV infection also contributes to cardiovascular disease, bone disease, renal and hepatic dysfunction and several other common morbidities. Antiretroviral drugs are highly effective at inhibiting HIV replication, and for individuals who can access and adhere to these drugs, combination antiretroviral therapy leads to durable (and probably lifelong) suppression of viral replication. Viral suppression enables immune recovery and the near elimination of the risk for developing acquired immune deficiency syndrome (AIDS). Despite effective treatment, HIV-infected individuals have a higher than expected risk of heart, bone, liver, kidney and neurological disease. When used optimally by an infected (or by an uninfected) person, antiretroviral drugs can virtually eliminate the risk of HIV transmission. Despite major advances in prevention sciences, HIV transmission remains common in many vulnerable populations, including men who have sex with men, injection drug users and sex workers. Owing to a lack of widespread HIV testing and the costs and toxicities associated with antiretroviral drugs, the majority of the infected population is not on effective antiretroviral therapy. To reverse the pandemic, improved prevention, treatment and implementation approaches are necessary.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: HIV infection and AIDS.
Figure 2: HIV care cascade.
Figure 3: Key milestones in history of HIV research and care.
Figure 4: The HIV life cycle.
Figure 5: T cell depletion.
Figure 6: HIV prevention strategies.
Figure 7: Quality of life impairment in individuals with HIV infection.
Figure 8: Shock and kill for the cure.


  1. 1

    Faria, N. R. et al. HIV epidemiology. The early spread and epidemic ignition of HIV-1 in human populations. Science 346, 56–61 (2014).

  2. 2

    Keele, B. F. et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313, 523–526 (2006).

  3. 3

    Gottlieb, M. S. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305, 1425–1431 (1981).

  4. 4

    Barre-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868–871 (1983).

  5. 5

    Gallo, R. C. et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 220, 865–867 (1983).

  6. 6

    UN Joint Programme on HIV/AIDS. MDG 6: 15 years, 15 lessons of hope from the AIDS response. Fact sheet. UNAIDS[online], (2015).

  7. 7

    GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385, 117–171 (2015).

  8. 8

    Moir, S., Chun, T. W. & Fauci, A. S. Pathogenic mechanisms of HIV disease. Annu. Rev. Pathol. 6, 223–248 (2011).

  9. 9

    Haase, A. T. Perils at mucosal front lines for HIV and SIV and their hosts. Nat. Rev. Immunol. 5, 783–792 (2005).

  10. 10

    Mellors, J. W. et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167–1170 (1996).

  11. 11

    McCune, J. M. The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974–979 (2001).

  12. 12

    Deeks, S. G. & Walker, B. D. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27, 406–416 (2007).

  13. 13

    Davey, R. T. Jr et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109–15114 (1999).

  14. 14

    UN Joint Programme on HIV/AIDS. The Gap Report. Refworld[online], (2014). With a global modelling effort, UNAIDS produce detailed estimates of trends in the pandemic that are crucial for global advocacy.

  15. 15

    Beyrer, C. et al. The increase in global HIV epidemics in MSM. AIDS 27, 2665–2678 (2013).

  16. 16

    UN Joint Programme on HIV/AIDS. Global Report. UNAIDS reports on the global AIDS epidemic 2013. UNAIDS[online], (2013).

  17. 17

    Shisana, O. et al. South African National HIV Prevalence, Incidence and Behaviour Survey, 2012 (HSRC Press, 2014).

  18. 18

    Gregson, S. et al. HIV decline in Zimbabwe due to reductions in risky sex? Evidence from a comprehensive epidemiological review. Int. J. Epidemiol. 39, 1311–1323 (2010).

  19. 19

    Rosen, S. & Fox, M. P. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 8, e1001056 (2011).

  20. 20

    McMahon, J. H., Elliott, J. H., Hong, S. Y., Bertagnolio, S. & Jordan, M. R. Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review. PLoS ONE 8, e56047 (2013).

  21. 21

    Wu, L. & KewalRamani, V. N. Dendritic-cell interactions with HIV: infection and viral dissemination. Nat. Rev. Immunol. 6, 859–868 (2006).

  22. 22

    Zeng, M. et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 121, 998–1008 (2011).

  23. 23

    Estes, J. D. et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor β1-positive regulatory T cells and begins in early infection. J. Infect. Dis. 195, 551–561 (2007).

  24. 24

    Sanchez, J. L. et al. Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. J. Infect. Dis. 211, 1068–1075 (2015).

  25. 25

    Zeng, M. et al. Lymphoid tissue damage in HIV-1 infection depletes naive T cells and limits T cell reconstitution after antiretroviral therapy. PLoS Pathog. 8, e1002437 (2012).

  26. 26

    Overbaugh, J. & Bangham, C. R. Selection forces and constraints on retroviral sequence variation. Science 292, 1106–1109 (2001).

  27. 27

    Shankarappa, R. et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73, 10489–10502 (1999).

  28. 28

    Piantadosi, A. et al. HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response. AIDS 23, 579–587 (2009).

  29. 29

    Korber, B. et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19–42 (2001).

  30. 30

    Spira, A. I. et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 183, 215–225 (1996).

  31. 31

    Zhang, Z. et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 286, 1353–1357 (1999).

  32. 32

    Miller, C. J. et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 79, 9217–9227 (2005).

  33. 33

    Sagar, M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J. Infect. Dis. 202, S289–S296 (2010).

  34. 34

    Keele, B. F. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552–7557 (2008).

  35. 35

    Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S. & Landau, N. R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621–628 (1997).

  36. 36

    Scarlatti, G. et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3, 1259–1265 (1997).

  37. 37

    Long, E. M., Rainwater, S. M., Lavreys, L., Mandaliya, K. & Overbaugh, J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses 18, 567–576 (2002).

  38. 38

    Dean, M. et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273, 1856–1862 (1996).

  39. 39

    Sheppard, H. W. et al. HIV-1 infection in individuals with the CCR5-Δ32/Δ32 genotype: acquisition of syncytium-inducing virus at seroconversion. J. Acquir. Immune Defic. Syndr. 29, 307–313 (2002).

  40. 40

    Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367–377 (1996).

  41. 41

    Samson, M. et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722–725 (1996).

  42. 42

    Sagar, M. Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. J. Infect. Dis. 210, S667–S673 (2014).

  43. 43

    Redd, A. D. et al. Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J. Infect. Dis. 206, 1433–1442 (2012).

  44. 44

    Derdeyn, C. A. et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303, 2019–2022 (2004).

  45. 45

    Chohan, B. et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1–V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J. Virol. 79, 6528–6531 (2005).

  46. 46

    Gnanakaran, S. et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 7, e1002209 (2011).

  47. 47

    Fenton-May, A. E. et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 10, 146 (2013).

  48. 48

    Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl Acad. Sci. USA 110, 6626–6633 (2013).

  49. 49

    Stacey, A. R. et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J. Virol. 83, 3719–3733 (2009).

  50. 50

    Sandler, N. G. et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511, 601–605 (2014).

  51. 51

    Kelley, C. F., Barbour, J. D. & Hecht, F. M. The relation between symptoms, viral load, and viral load set point in primary HIV infection. J. Acquir. Immune Defic. Syndr. 45, 445–448 (2007).

  52. 52

    Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650–4655 (1994).

  53. 53

    Richardson, B. A. et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J. Virol. 77, 7120–7123 (2003).

  54. 54

    Lyles, R. H. et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. J. Infect. Dis. 181, 872–880 (2000).

  55. 55

    Kimata, J. T., Kuller, L., Anderson, D. B., Dailey, P. & Overbaugh, J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5, 535–541 (1999).

  56. 56

    Hecht, F. M. et al. HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 24, 941–945 (2010).

  57. 57

    Obimbo, E. M. et al. Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J. Acquir. Immune Defic. Syndr. 51, 209–215 (2009).

  58. 58

    Fraser, C. et al. Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective. Science 343, 1243727 (2014).

  59. 59

    Alizon, S. et al. Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS Pathog. 6, e1001123 (2010).

  60. 60

    Buzon, M. J. et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat. Med. 20, 139–142 (2014).

  61. 61

    Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893–900 (2009).

  62. 62

    Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).

  63. 63

    Wong, J. K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291–1295 (1997).

  64. 64

    Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183–188 (1997).

  65. 65

    Chun, T. W. et al. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl Acad. Sci. USA 95, 8869–8873 (1998).

  66. 66

    Whitney, J. B. et al. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512, 74–77 (2014).

  67. 67

    Buzon, M. J. et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 16, 460–465 (2010).

  68. 68

    Hatano, H. et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV Infection: a randomized, placebo-controlled trial. J. Infect. Dis. 208, 1436–1442 (2013).

  69. 69

    Fletcher, C. V. et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc. Natl Acad. Sci. USA 111, 2307–2312 (2014).

  70. 70

    Fukazawa, Y. et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat. Med. 21, 132–139 (2015).

  71. 71

    Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9, 727–728 (2003). This longitudinal study demonstrates that HIV persists at low levels indefinitely even during effective combination ART. Antiretroviral drugs must, therefore, be given indefinitely to prevent viral rebound.

  72. 72

    Fellay, J. et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944–947 (2007).

  73. 73

    Pereyra, F. et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551–1557 (2010).

  74. 74

    Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006).

  75. 75

    Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198–1202 (2006).

  76. 76

    Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381–385 (2015).

  77. 77

    Lewis, G. K. Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 142, 46–57 (2014).

  78. 78

    Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307–312 (2003).

  79. 79

    West, A. P. Jr et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633–648 (2014).

  80. 80

    Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002).

  81. 81

    Laguette, N. et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 474, 654–657 (2011).

  82. 82

    Neil, S. J., Zang, T. & Bieniasz, P. D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451, 425–430 (2008).

  83. 83

    Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F. & Heard, J. M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2, 338–342 (1996).

  84. 84

    Redd, A. D., Quinn, T. C. & Tobian, A. A. Frequency and implications of HIV superinfection. Lancet Infect. Dis. 13, 622–628 (2013).

  85. 85

    Ronen, K. et al. HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women. PLoS Pathog. 9, e1003593 (2013).

  86. 86

    Brenchley, J. M. et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365–1371 (2006).

  87. 87

    Giorgi, J. V. et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J. Acquir. Immune Defic. Syndr. 29, 346–355 (2002).

  88. 88

    Deeks, S. G. et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104, 942–947 (2004).

  89. 89

    Doitsh, G. et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature 505, 509–514 (2014).

  90. 90

    Quinn, T. C. et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N. Engl. J. Med. 342, 921–929 (2000).

  91. 91

    Baeten, J. M. et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci. Transl. Med. 3, 77ra29 (2011).

  92. 92

    Rottingen, J. A., Cameron, D. W. & Garnett, G. P. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex. Transm. Dis. 28, 579–597 (2001).

  93. 93

    Weiss, H. A., Quigley, M. A. & Hayes, R. J. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 14, 2361–2370 (2000).

  94. 94

    Lemos, M. P. et al. The inner foreskin of healthy males at risk of HIV infection harbors epithelial CD4+ CCR5+ cells and has features of an inflamed epidermal barrier. PLoS ONE 9, e108954 (2014).

  95. 95

    Hirbod, T. et al. HIV acquisition is associated with increased antimicrobial peptides and reduced HIV neutralizing IgA in the foreskin prepuce of uncircumcised men. PLoS Pathog. 10, e1004416 (2014).

  96. 96

    Dinh, M. H. et al. Visualization of HIV-1 interactions with penile and foreskin epithelia: clues for female-to-male HIV transmission. PLoS Pathog. 11, e1004729 (2015).

  97. 97

    Polis, C. B. & Curtis, K. M. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect. Dis. 13, 797–808 (2013). This is an excellent synthesis of the evidence for and against the role of hormonal contraception increasing HIV infection acquisition in women.

  98. 98

    Carnegie, N. B. & Morris, M. Size matters: concurrency and the epidemic potential of HIV in small networks. PLoS ONE 7, e43048 (2012).

  99. 99

    New York State Department of Health. Quick reference guide — laboratory testing for the diagnosis of HIV infection: updated recommendations. CDC[online], (2014).

  100. 100

    Gokengin, D. et al. 2014 European guideline on HIV testing. Int. J. STD AIDS 25, 695–704 (2014).

  101. 101

    Hollingsworth, T. D., Anderson, R. M. & Fraser, C. HIV-1 transmission, by stage of infection. J. Infect. Dis. 198, 687–693 (2008).

  102. 102

    Bellan, S. E., Dushoff, J., Galvani, A. P. & Meyers, L. A. Reassessment of HIV-1 acute phase infectivity: accounting for heterogeneity and study design with simulated cohorts. PLoS Med. 12, e1001801 (2015).

  103. 103

    Hollingsworth, T. D., Pilcher, C. D., Hecht, F. M., Deeks, S. G. & Fraser, C. High transmissibility during early HIV infection among men who have sex with men — San Francisco, California. J. Infect. Dis. 211, 1757–1760 (2015).

  104. 104

    Marks, G., Crepaz, N. & Janssen, R. S. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS 20, 1447–1450 (2006).

  105. 105

    Pilcher, C. D. et al. Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco. PLoS ONE 8, e80629 (2013).

  106. 106

    Amor, A. et al. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 20, 1460–1462 (2006).

  107. 107

    Moyer, V. A. & U.S. Preventative Services Task Force. Screening for HIV: U.S. Preventive Services Task Force Recommended Statement. Ann. Intern. Med. 159, 51–60 (2013).

  108. 108

    World Health Organization. Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations (WHO Press, 2014).

  109. 109

    Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 55, 1–17 (2006).

  110. 110

    Zetola, N. M. et al. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003–June 2007. PLoS ONE 3, e2591 (2008).

  111. 111

    Haukoos, J. S. et al. Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients. JAMA 304, 284–292 (2010).

  112. 112

    Baisley, K. et al. Uptake of voluntary counselling and testing among young people participating in an HIV prevention trial: comparison of opt-out and opt-in strategies. PLoS ONE 7, e42108 (2012).

  113. 113

    Weller, S. & Davis, K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst. Rev. 1, CD003255 (2002).

  114. 114

    Smith, D. K., Herbst, J. H., Zhang, X. & Rose, C. E. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J. Acquir. Immune Defic. Syndr. 68, 337–344 (2015).

  115. 115

    Remis, R. S., Alary, M., Liu, J., Kaul, R. & Palmer, R. W. HIV transmission among men who have sex with men due to condom failure. PLoS ONE 9, e107540 (2014).

  116. 116

    Aspinall, E. J. et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. Int. J. Epidemiol. 43, 235–248 (2014).

  117. 117

    Nduati, R., Mbori-Ngacha, D., John, G., Richardson, B. & Kreiss, J. Breastfeeding in women with HIV. JAMA 284, 956–957 (2000).

  118. 118

    de Vincenzi, I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect. Dis. 11, 171–180 (2011).

  119. 119

    Mofenson, L. M. Prevention in neglected subpopulations: prevention of mother-to-child transmission of HIV infection. Clin. Infect. Dis. 50, S130–S148 (2010).

  120. 120

    World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach (WHO Press, 2013). WHO guidelines for a public health approach to ART provision have been crucial in guiding the rollout of ART. The most recent guidelines expanded the eligibility criteria for ART initiation substantially.

  121. 121

    Auvert, B. et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2, e298 (2005).

  122. 122

    Bailey, R. C. et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643–656 (2007).

  123. 123

    Gray, R. H. et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657–666 (2007).

  124. 124

    Gray, R. H. et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. Aids 26, 609–615 (2012).

  125. 125

    Wawer, M. J. et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 374, 229–237 (2009).

  126. 126

    Gray, R. H. et al. Effects of genital ulcer disease and herpes simplex virus type 2 on the efficacy of male circumcision for HIV prevention: analyses from the Rakai trials. PLoS Med. 6, e1000187 (2009).

  127. 127

    UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention. Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med. 6, e1000109 (2009).

  128. 128

    Goodreau, S. M. et al. Can male circumcision have an impact on the HIV epidemic in men who have sex with men? PLoS ONE 9, e102960 (2014).

  129. 129

    Cohen, M. S. et al. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365, 493–505 (2011). This paper presents a randomized controlled trial of early versus standard initiation of ART to prevent transmission of HIV to an uninfected sexual partner.

  130. 130

    Rodger, A. et al. Abtract 153LB: HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. NAPWHA[online], (2014).

  131. 131

    Grulich, A. E. et al. HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil. CROI[online], (2015).

  132. 132

    Mujugira, A. et al. HIV-1 transmission risk persists during the first 6 months of antiretroviral therapy. CROI[online], (2015).

  133. 133

    Gardner, L. I. et al. Time above 1500 copies/ml: a viral-load measure for assessing transmission risk of HIV-positive patients in care. AIDS 29, 947–954 (2015).

  134. 134

    Tsai, C. C. et al. Prevention of SIV infection in macaques by (R)-9-(2- phosphonylmethoxypropyl)adenine. Science 270, 1197–1199 (1995).

  135. 135

    Cardo, D. M. et al. A case–control study of HIV seroconversion in health care workers after percutaneous exposure. N. Engl. J. Med. 337, 1485–1490 (1997).

  136. 136

    Kuhar, D. T. et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect. Control Hosp. Epidemiol. 34, 875–892 (2013). These are the most recent guidelines for post-exposure prophylaxis in the United States.

  137. 137

    Joyce, P. M., Kuhar, D. & Brooks, J. T. Occupationally acquired HIV infection by healthcare personnel – United States, 1985–2013 (poster). CROI[online], (2015).

  138. 138

    McCormack, S. & Dunn, D. Pragmatic open-label randomised trial of preexposure prophylaxis: the PROUD study. CROI[online], (2015).

  139. 139

    Baeten, J. M. et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367, 399–410 (2012).

  140. 140

    Grant, R. M. et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363, 2587–2599 (2010).

  141. 141

    Choopanya, K. et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 381, 2083–2090 (2013).

  142. 142

    Marrazzo, J. M. et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).

  143. 143

    Van Damme, L. et al. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367, 411–422 (2012).

  144. 144

    Anderson, P. L. et al. Emtricitabine–tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci. Transl. Med. 4, 151ra125 (2012). This paper explores the potential ‘forgiveness’ of less than daily dosing of TDF/FTC pre-exposure prophylaxis.

  145. 145

    Kashuba, A. D. et al. Genital tenofovir concentrations correlate with protection against HIV infection in the CAPRISA 004 trial. J. Acquir. Immine Defic. Syndr. 69, 264–269 (2015).

  146. 146

    Molina, J. M. et al. On demand PrEP with oral TDF–FTC in MSM: results of the ANRS Ipergay trial. CROI[online], (2015).

  147. 147

    World Health Organization. Guidance on Oral Pre-Exposure Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV (WHO Press, 2012).

  148. 148

    Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 60, 65–68 (2011). These are the most recent pre-exposure prophylaxis guidelines from the Centers for Disease Control and Prevention.

  149. 149

    Smith, D. et al. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. MMWR 62, 463–465 (2013).

  150. 150

    National Institute of Allergy and Infectious Diseases. Evaluating the safety, tolerability, and pharmacokinetics of an investigational, injectable HIV medicine (GSK1265744) in HIV-uninfected adults.[online], (2014).

  151. 151

    International Partnership for Microbicides, Inc. Safety and efficacy trial of a dapivirine vaginal matrix ring in healthy HIV-negative women.[online], (2012).

  152. 152

    International Partnership for Microbicides, Inc. Phase 3 safety and effectiveness trial of dapivirine vaginal ring for prevention of HIV-1 in women (ASPIRE).[online], (2012).

  153. 153

    Tellalian, D., Maznavi, K., Bredeek, U. F. & Hardy, W. D. Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. AIDS Patient Care STDS 27, 553–559 (2013).

  154. 154

    Barouch, D. H. & Picker, L. J. Novel vaccine vectors for HIV-1. Nat. Rev. Microbiol. 12, 765–771 (2014).

  155. 155

    Haynes, B. F. & Bradley, T. Broadly neutralizing antibodies and the development of vaccines. JAMA 313, 2419–2420 (2015). This is an excellent and clear summary of the search for correlates of protection from a successful HIV vaccine trial.

  156. 156

    Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 502, 100–104 (2013).

  157. 157

    Rerks-Ngarm, S. et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209–2220 (2009).

  158. 158

    Haynes, B. F. et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275–1286 (2012).

  159. 159

    Hallett, T. B. et al. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS ONE 3, e2212 (2008). This paper demonstrates the potential for synergies from combining different prevention modalities.

  160. 160

    HIV Prevention Trials Network. Population effects of antiretroviral therapy to reduce HIV Transmission (PopART).[online], (2013).

  161. 161

    Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568–579 (2008).

  162. 162

    Sabin, C. A. et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371, 1417–1426 (2008).

  163. 163

    Taiwo, B. et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 25, 2113–2122 (2011).

  164. 164

    Cahn, P. et al. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect. Dis. 14, 572–580 (2014).

  165. 165

    Clotet, B. et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383, 2222–2231 (2014).

  166. 166

    Walmsley, S. L. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N. Engl. J. Med. 369, 1807–1818 (2013).

  167. 167

    Raffi, F. et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect. Dis. 13, 927–935 (2013).

  168. 168

    Lennox, J. L. et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann. Intern. Med. 161, 461–471 (2014).

  169. 169

    Rockstroh, J. K. et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin. Infect. Dis. 53, 807–816 (2011).

  170. 170

    DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. AIDSinfo[online], (2015).

  171. 171

    Mollan, K. R. et al. Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Ann. Intern. Med. 161, 1–10 (2014).

  172. 172

    Puls, R. et al. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383, 1474–1482 (2014).

  173. 173

    Cohen, C. et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 28, 989–997 (2014).

  174. 174

    Günthard, H. F. et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312, 410–425 (2014).

  175. 175

    Acosta, E. P. et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob. Agents Chemother. 56, 5938–5945 (2012).

  176. 176

    Friis-Møller, N. et al. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723–1735 (2007).

  177. 177

    Severe, P. et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N. Engl. J. Med. 363, 257–265 (2010).

  178. 178

    Grinsztejn, B. et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect. Dis. 14, 281–290 (2014).

  179. 179

    Emery, S. et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J. Infect. Dis. 197, 1133–1144 (2008).

  180. 180

    Williams, I. et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 13, S1–S85 (2012).

  181. 181

    The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N. Engl. J. Med. 373, 808–822 (2015).

  182. 182

    The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N. Engl. J. Med. 373, 795–807 (2015).

  183. 183

    Hatano, H. et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 9, e1003691 (2013).

  184. 184

    Paredes, R. et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J. Infect. Dis. 201, 662–671 (2010).

  185. 185

    Deeks, S. G. et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344, 472–480 (2001).

  186. 186

    Bangsberg, D. R. et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 20, 223–231 (2006).

  187. 187

    Little, S. J. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347, 385–394 (2002).

  188. 188

    Vercauteren, J. et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J. Infect. Dis. 200, 1503–1508 (2009).

  189. 189

    Rhee, S. Y. et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 12, e1001810 (2015).

  190. 190

    Pham, Q. D., Wilson, D. P., Law, M. G., Kelleher, A. D. & Zhang, L. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS 28, 2751–2762 (2014).

  191. 191

    Miners, A. et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV 1, e32–e40 (2014).

  192. 192

    Phillips, A. N., Neaton, J. & Lundgren, J. D. The role of HIV in serious diseases other than AIDS. AIDS 22, 2409–2418 (2008).

  193. 193

    Deeks, S. G., Lewin, S. R. & Havlir, D. V. The end of AIDS: HIV infection as a chronic disease. Lancet 382, 1525–1533 (2013).

  194. 194

    Freiberg, M. S. et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern. Med. 173, 614–622 (2013).

  195. 195

    Kuller, L. H. et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5, e203 (2008). This retrospective analysis of a randomized clinical trial provides the first definitive evidence that HIV-mediated inflammation predicted development of non-AIDS morbidity and mortality that is independent of other factors.

  196. 196

    Worm, S. W. et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J. Infect. Dis. 201, 318–330 (2010).

  197. 197

    Ryom, L. et al. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J. Infect. Dis. 207, 1359–1369 (2013).

  198. 198

    Deeks, S. G., Tracy, R. & Douek, D. C. Systemic effects of inflammation on health during chronic HIV infection. Immunity 39, 633–645 (2013).

  199. 199

    Brothers, T. D. et al. Frailty in people aging with human immunodeficiency virus (HIV) infection. J. Infect. Dis. 210, 1170–1179 (2014).

  200. 200

    Althoff, K. N. et al. Age, comorbidities, and AIDS predict a frailty phenotype in men who have sex with men. J. Gerontol. A Biol. Sci. Med. Sci. 69, 189–198 (2014).

  201. 201

    Rosen, S., Fox, M. P. & Gill, C. J. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 4, e298 (2007).

  202. 202

    Fox, M. P. & Rosen, S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007–2009: systematic review. Trop. Med. Int. Health 15, 1–16 (2010).

  203. 203

    Fox, M. P. & Rosen, S. Retention of adult patients on antiretroviral therapy in low-and middle-income countries: systematic review and meta-analysis 2008–2013. J. Acquir. Immune Defic. Syndr. 69, 98–108 (2015).

  204. 204

    Bradley, H. et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV — United States, 2011. MMWR 63, 1113–1117 (2014).

  205. 205

    University of California, San Francisco. Sustainable East Africa research in community health (SEARCH).[online], (2013).

  206. 206

    Centers for Disease Control and Prevention. Botswana Combination Prevention Project (BCPP).[online], (2013).

  207. 207

    Inserm-ANRS. Impact of immediate versus South African recommendations guided ART initiation on HIV incidence (TasP).[online], (2012).

  208. 208

    Phillips, A. N. et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS 29, 1855–1862 (2015).

  209. 209

    Thompson, M. A. et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann. Intern. Med. 156, 817–833 (2012).

  210. 210

    Andrews, C. D. et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci. Transl. Med. 7, 270ra274 (2015).

  211. 211

    Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).

  212. 212

    Picker, L. J., Hansen, S. G. & Lifson, J. D. New paradigms for HIV/AIDS vaccine development. Annu. Rev. Med. 63, 95–111 (2012). This paper outlines the challenges and potential strategies for developing an effective HIV vaccine.

  213. 213

    Hansen, S. G. et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523–527 (2011). This elegant study demonstrated that a vaccine could induce potent SIV-specific effector CD8+ T cells and that these cells can eradicate established retroviral infection.

  214. 214

    Fauci, A. S., Marston, H. D. & Folkers, G. K. An HIV cure: feasibility, discovery, and implementation. JAMA 312, 335–336 (2014).

  215. 215

    Hutter, G. et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698 (2009). This provocative case report demonstrated that HIV infection can be cured with a haematopoietic stem cell transplant and has inspired a robust international effort to develop a curative intervention.

  216. 216

    Yukl, S. A. et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347 (2013).

  217. 217

    Sáez-Cirión, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9, e1003211 (2013).

  218. 218

    UN Joint Programme on HIV/AIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. UNAIDS[online], (2013).

  219. 219

    Jewkes, R. K., Dunkle, K., Nduna, M. & Shai, N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet 376, 41–48 (2010).

  220. 220

    Centers for Disease Control and Prevention. Statistics Center — HIV/AIDS. CDC[online], (2015).

  221. 221

    Gandhi, M. et al. Does patient sex affect human immunodeficiency virus levels? Clin. Infect. Dis. 35, 313–322 (2002).

  222. 222

    Chang, J. J. et al. Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J. Infect. Dis. 208, 830–838 (2013).

  223. 223

    Triant, V. A., Lee, H., Hadigan, C. & Grinspoon, S. K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J. Clin. Endocrinol. Metab. 92, 2506–2512 (2007).

  224. 224

    Soon, G. G. et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy. AIDS Patient Care STDS 26, 444–453 (2012).

  225. 225

    Currier, J. et al. Sex-based outcomes of darunavir–ritonavir therapy: a single-group trial. Ann. Intern. Med. 153, 349–357 (2010).

  226. 226

    Loutfy, M. R. et al. Caring for women living with HIV: gaps in the evidence. J. Int. AIDS Soc. 16, 18509 (2013).

  227. 227

    Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. AIDSinfo[online], (2015).

  228. 228

    Marinda, E. et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr. Infect. Dis. J. 26, 519–526 (2007).

  229. 229

    Violari, A. et al. Early antiretroviral therapy and mortality among HIV-infected infants. N. Engl. J. Med. 359, 2233–2244 (2008).

  230. 230

    Puthanakit, T. et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect. Dis. 12, 933–941 (2012).

  231. 231

    Hazra, R., Siberry, G. K. & Mofenson, L. M. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu. Rev. Med. 61, 169–185 (2010).

  232. 232

    Ranasinghe, S. et al. Association of HLA-DRB1-restricted CD4+ T cell responses with HIV immune control. Nat. Med. 19, 930–933 (2013).

  233. 233

    Migueles, S. A. et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009–1021 (2008).

  234. 234

    Ferre, A. L. et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113, 3978–3989 (2009).

  235. 235

    Lelic, A. et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 8, e1003076 (2012).

  236. 236

    Martin, M. P. et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733–740 (2007).

  237. 237

    Emu, B. et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82, 5398–5407 (2008).

  238. 238

    Miura, T. et al. HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J. Virol. 83, 140–149 (2009).

  239. 239

    Chen, H. et al. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J. Clin. Invest. 121, 1549–1560 (2011).

  240. 240

    Abdel-Mohsen, M. et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 10, 106 (2013).

  241. 241

    Mocroft, A. et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 370, 407–413 (2007).

  242. 242

    Baker, J. V. et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS 22, 841–848 (2008).

  243. 243

    Lichtenstein, K. A. et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin. Infect. Dis. 51, 435–447 (2010).

  244. 244

    Serrano-Villar, S. et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 10, e1004078 (2014).

  245. 245

    Hunt, P. W. et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J. Infect. Dis. 210, 1228–1238 (2014).

  246. 246

    Tenorio, A. R. et al. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. J. Infect. Dis. 210, 1248–1259 (2014).

  247. 247

    Kelley, C. F. et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 48, 787–794 (2009).

  248. 248

    Okulicz, J. F. et al. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals. JAMA Intern. Med. 175, 88–99 (2015).

  249. 249

    Schneider, E. et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years — United States, 2008. MMWR 57, 1–12 (2008).

  250. 250

    Gulick, R. M. et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734–739 (1997).

  251. 251

    Engelman, A. & Cherepanov, P. The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 10, 279–290 (2012).

  252. 252

    Brenchley, J. M., Price, D. A. & Douek, D. C. HIV disease: fallout from a mucosal catastrophe? Nat. Immunol. 7, 235–239 (2006).

  253. 253

    Bonyhadi, M. L. et al. HIV induces thymus depletion in vivo. Nature 363, 728–732 (1993).

  254. 254

    Favre, D. et al. Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2, 32ra36 (2010).

  255. 255

    Sauce, D. et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood 117, 5142–5151 (2011).

  256. 256

    Patel, P. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509–1519 (2014).

Download references


The authors thank E. Abrams, J. Gallant, M. Gandhi, E. Geng, T. Ruel and S. Pillai for advice.

Author information

Introduction (S.G.D.); Epidemiology (S.G.D., A.P. and S.B.); Mechanisms/pathophysiology (S.G.D., J.O. and S.B.); Diagnosis, screening and prevention (S.G.D., J.O. and S.B.); Management (S.G.D. and A.P.); Quality of life (S.G.D. and A.P.); Outlook (S.G.D., J.O., A.P. and S.B.); overview of the Primer (S.G.D).

Correspondence to Steven G. Deeks.

Ethics declarations

Competing interests

S.G.D. has consulted for Bristol-Myers Squibb, GlaxoSmithKline, Novartis and Janssen, and has received research support from Gilead and Merck. A.P. has attended various advisory boards, has received speaker fees for meetings in the past 4 years for Gilead Sciences and has received research support from GlaxoSmithKline. J.O. and S.B. declare no competing interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Deeks, S., Overbaugh, J., Phillips, A. et al. HIV infection. Nat Rev Dis Primers 1, 15035 (2015).

Download citation

Further reading